Biomea Fusion made a bold move, as it announced today, May 5th of 2025, that it had decided to reduce its workforce, and one of the reasons being was to conserve cash. This cost-cutting measure is going to allow it be in a position...
Just the other day, Pliant Therapeutics announced that it would enact a strategic restructuring of its workforce in order to extend its cash runway. It intends to reduce its workforce by as much as 45% to implement this cost-cutting measure. This isn't something that...
Immunic reported data today from its phase 2 CALLIPER trial for its drug vidofludimus calcium (IMU-838) for the treatment of patients with progressive multiple sclerosis (PMS). The data itself was mixed because there was actually a miss on one of the endpoints that was...
Things went very well today for Abeona Therapeutics because it had received FDA approval of the first and only autologous cell-based gene therapy for the treatment of adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) as a one-time application. This is a...
Pfizer seemed to have a good win over this past weekend because it presented positive results from its phase 3 CREST study, which used anti-PD-1 monoclonal antibody (mAb) sasanlimab in combination with current standard of care (SOC) Bacillus Calmette-Guerin (BCG) for the treatment of...
Caribou Biosciences announced today that it will reprioritize its pipeline and focus on two specific clinical candidates. These two specific candidates are CB-010 for the treatment of patients with large B cell lymphoma and CB-011 for the treatment of patients with Multiple Myeloma (MM)....
